In the past few years 3D printing has become the next big trend on the horizon and it has now turned its sights onto the pharmaceutical industry… A few days ago the FDA approved the world’s first 3D printed drug; Aprecia’s Spritam and will be used for treating epilepsy. One of the many benefits of
The MHRA (Medicines and Healthcare products Regulatory Agency), a government agency responsible for ensuring that medicines and medical devices work and are acceptably safe, has revealed their new anti-counterfeiting policy to increase the clamp down on fake drugs arriving in the UK supply chain. Developing on the achievements of the initial action plan, the new
UK MPs have been told that regulatory proposals currently being considered for quicker entrance for medicines which meet key unmet medical needs provide an opportunity for small life science businesses to grow to middle-sized organisations. In December 2011, the UK’s Prime Minister, David Cameron, announced that, as part of the Life Sciences Strategy, the MHRA
Eisai has received mixed news this week, after news that Dacogen, Eisai and Astex Pharmaceuticals’ drug to treat a type of leukaemia, has been rejected by an independent advisory panel to the regulator in the USA. The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee voted 10 to 3 that statistics in Eisai’s
